Antares Pharma : Social Media Campaign for XYOSTED Wins Marcom Platinum Award

EWING - Antares Pharma, Inc. (NASDAQ: ATRS) ('Antares') ('the Company') today announced that the Company's social media campaign for XYOSTED, has been honored with a 2019 MarCom Platinum Award.

The award is the highest level achievable in the international marketing competition.

The social media campaign for XYOSTED featured a series of Facebook and Instagram ads to prime existing testosterone deficient patients for the launch of a new testosterone replacement therapy. The ads used humor and arresting imagery which focused on the challenges of other testosterone therapies such as messy application of testosterone gels and painful intramuscular injections. XYOSTED is a once weekly, virtually painless subcutaneous injection of testosterone which can restore men's testosterone levels into the normal range. The social media campaign competed with other lifestyle content on the social platforms, with results that exceeded initial expectations.

'We are honored to be recognized by the Association of Marketing and Communication Professionals with such a prestigious award for our XYOSTED social media campaign. Extensive market research with testosterone deficient patients helped us understand the compromises they were making with their current treatment options. We wanted to potentially help these patients, by making them aware of a new treatment option,' said Robert F. Apple, President and Chief Executive Officer of the Company. 'We believe that many of our prescribers and patients see the benefits of XYOSTED, a once weekly subcutaneous, virtually pain-free treatment option.'

About Hypogonadism

Hypogonadism, also known as testosterone deficiency or Low T, is a condition in which the body does not produce enough testosterone - the hormone that plays a key role in masculine growth and development during puberty, and maintenance of musculoskeletal, metabolic, and mental health in maturity. Symptoms of male hypogonadism can be treated with testosterone replacement therapy.

About Antares Pharma

Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's proprietary products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: impact of the social media campaign on future XYOSTED prescriptions, market acceptance, adequate reimbursement coverage and commercial success of XYOSTED and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena subcutaneous auto injector; Teva's ability to successfully commercialize VIBEX Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP; the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; achievement of the 2019 revised revenue guidance; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as 'may', 'will', 'should', 'would', 'expect', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'predict', 'potential', 'seem', 'seek', 'future', 'continue', or 'appear' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the 'Risk Factors' section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contact:

Jack Howarth

Tel: [phone]

Email: [e-mail]

(C) 2019 Electronic News Publishing, source ENP Newswire